Quince Therapeutics
QNCX
62 hedge funds and large institutions have $67.5M invested in Quince Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 4 closing their positions.
525% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 4
400% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 4
251% more capital invested
Capital invested by funds: $19.2M → $67.5M (+$48.3M)
51% more funds holding
Funds holding: 41 → 62 (+21)
47% more call options, than puts
Call options by funds: $396K | Put options by funds: $270K
0.07% more ownership
Funds ownership: 0.11% → 0.18% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.66M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$4.88M |
| 3 |
SCM
Superstring Capital Management
New York
|
+$2.16M |
| 4 |
SC
Stempoint Capital
New York
|
+$1.86M |
| 5 |
Jane Street
New York
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.84M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.01M |
| 3 |
Millennium Management
New York
|
-$494K |
| 4 |
SC
Shay Capital
New York
|
-$223K |
| 5 |
Mariner
Overland Park,
Kansas
|
-$200K |
QNCX Hedge Fund Activity: Q4 2025 in Review
62 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q4 2025, worth a combined $67.5M — up 251% from $19.2M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new QNCX positions and 4 closed out — a net gain of 21 holders — while 20 added to existing stakes and 4 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $5.66M. The largest seller was ADAR1 Capital Management, cutting an estimated $1.84M.
- 62 institutional investors held Quince Therapeutics (QNCX) as of Q4 2025, up from 41 in Q3 2025.
- Funds reported $67.5M of Quince Therapeutics stock for Q4 2025, up 251% quarter-over-quarter.
- 25 funds opened new Quince Therapeutics positions in Q4 2025 and 4 closed out, a net change of +21 holders.
- The largest Quince Therapeutics buyer in Q4 2025 was Adage Capital Partners, an estimated $5.66M added.
- The largest Quince Therapeutics seller in Q4 2025 was ADAR1 Capital Management, an estimated $1.84M sold.
Based on aggregated 13F filings for Q4 2025.